ERBB2 and invasive breast carcinoma: The second patient is a 75-year-old woman with left breast invasive carcinoma (ER+, PR weak, HER2-, PIK3CA gain of function mutation, PTEN truncating mutation, two TP53 missense mutations), status post neoadjuvant docetaxel and cyclophosphamide, left breast conservation therapy, radiation therapy, and aromatase inhibitor therapy.